<DOC>
	<DOCNO>NCT00129389</DOCNO>
	<brief_summary>This prospective , open-label , randomize , phase III trial . Patients stratify breast surgery , per investigational site ; menopausal status ; node negative diagnosis , per sentinel-node technique versus lymphadenectomy ; hormone receptor status ( positive versus negative ) . Patients randomize : - FAC x 6 ( cycle ) : 5-fluorouracil 500 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2 day 1 , every 3 week , 6 cycle . - FAC x 4 ( cycle ) → Taxol® x 8 ( cycle ) : 5-fluorouracil 500 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2 day 1 , every 3 week , 4 cycle , follow 8 administration weekly paclitaxel 100 mg/m2 Premenopausal woman hormone receptor positive tumor must receive tamoxifen 20 mg daily 5 year , end chemotherapy . Postmenopausal woman hormone receptor positive tumor allow receive aromatase inhibitor initial adjuvant hormone therapy tamoxifen . All patient breast conservative surgery must receive radiotherapy . Estimated 5-year disease-free survival control arm ( FAC x 6 ) expect 80 % . It expect disease-free survival increase 5 % experimental arm ( FAC-paclitaxel ) . 906 patient per arm must recruit , detect difference alpha error 0.05 80 % power . Assuming 6 % post-randomization drop-out rate , 960 patient per arm need , 1920 total .</brief_summary>
	<brief_title>FAC Versus FAC Plus Weekly Paclitaxel Adjuvant Treatment Node Negative High Risk Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Written inform consent . Histological diagnosis operable invasive adenocarcinoma breast ( T1T3 ) . Tumors must HER2 negative . Patients must free disease axilla ( node negative ) . If lymphadenectomy do , least 10 node must examine . If sentinel node technique use , sentinel node must free disease . Patients must present least one high risk criterion ( St. Gallen , 1998 ) follow : Tumor size &gt; 2 cm ; and/or ER PgR negative ; and/or Histological grade 23 ; and/or Age &lt; 35 year old . Time window surgery study randomization must less 60 day . Surgery must consist mastectomy conservative surgery . Margins free disease ductal carcinoma situ ( DCIS ) require . Lobular carcinoma consider positive margin . Patients must present evidence metastatic disease . Status hormone receptor primary tumor . Results must available end adjuvant chemotherapy . Status HER2 primary tumor , know randomization . Patients immune histochemistry ( IHC ) 0 +1 eligible . For patient ICH 2+ , fluorescent situ hybridization ( FISH ) mandatory result must negative . Age &gt; = 18 &lt; = 70 year old . Performance status ( Karnofsky index ) &gt; = 80 . Normal electrocardiogram ( EKG ) 12 week prior randomization . If need , normal cardiac function must confirm leave ventricular ejection fraction ( LVEF ) . Laboratory result ( within 14 day prior randomization ) : Hematology : neutrophil &gt; = 1.5 x 10^9/l ; platelet &gt; = 100x 10^9/l ; hemoglobin &gt; = 10 mg/dl ; Hepatic function : total bilirubin &lt; = 1 upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5 UNL ; alkaline phosphatase &lt; = 2.5 UNL . If value SGOT SGPT &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL , patient eligible . Renal function : creatinine &lt; = 175 mmol/l ( 2 mg/dl ) ; creatinine clearance &gt; = 60 ml/min . Complete stage workup 12 week prior randomization ( mammogram allow within 20 week time window ) . All patient must bilateral mammogram , thorax xray , abdominal echography and/or compute tomography ( CT ) scan . If bone pain , and/or alkaline phosphatase elevation , bone scintigraphy mandatory . This test recommend patient . Other test , clinically indicate . Patients able comply treatment study followup . Negative pregnancy test do 14 previous day randomization . Prior systemic therapy breast cancer . Prior therapy anthracyclines taxanes ( paclitaxel docetaxel ) malignancy . Prior radiotherapy breast cancer . Bilateral invasive breast cancer . Pregnant lactating woman . Adequate contraceptive method must use chemotherapy hormone therapy treatment . Negative pregnancy test 14 previous day randomization . Any T4 N13 M1 tumor . HER2 positive breast cancer ( IHC 3+ positive FISH result ) . Preexisting grade &gt; =2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria [ NCI CTC ] v2.0 ) . Any serious medical pathology , congestive heart failure , unstable angina , history myocardial infarction previous year , uncontrolled HA high risk arrhythmias . History neurological psychiatric disorder , could preclude patient free informed consent . Active uncontrolled infection . Active peptic ulcer ; unstable diabetes mellitus . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumor curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . Concomitant treatment investigational product . Participation clinical trial nonmarketed drug 20 previous day randomization . Concomitant treatment therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Node negative , high risk breast cancer .</keyword>
	<keyword>Prognostic gene profile .</keyword>
	<keyword>Saint Gallen high risk criterion .</keyword>
	<keyword>Weekly paclitaxel .</keyword>
</DOC>